NEW YORK – Roche announced on Thursday that it has entered a share purchase agreement to acquire 100 percent of the outstanding shares of the TIB Molbiol Group.
The deal is expected to close in the fourth quarter of 2021. Financial and other terms were not disclosed.
Roche said in a statement that the acquisition will enhance its portfolio of molecular diagnostic solutions for infectious diseases. TIB Molbiol currently has more than 45 CE-IVD marked tests and more than 100 research use assays that are available on Roche's LightCycler PCR and MagNA Pure sample prep systems, Roche said.
Berlin-based TIB Molbiol also has diagnostic tests for inherited genetic and somatic mutation testing and quantitative assays for hematology and transplantation medicine.
The companies have collaborated on infectious disease tests for more than 20 years, including developing the first research-use-only SARS-CoV-2 detection test in January 2020, Roche said.
"With this acquisition, we can expand our offering of tests of existing pathogens and our response to emerging pathogens and potential health threats," Thomas Schinecker, CEO of Roche Diagnostics, said in a statement.